Vindi Biosystems

Over het initiatief / About the initiative

In welke fase zit jouw initiatief? / In what stage is your initiative?

Uitgewerkt conceptfase

Heb je jouw initiatief al gevalideerd? / Did you validate your initiative?

Yes, we have validated our concept through over 200 interviews with clinicians and key opinion leaders across healthcare. Additionally, one of our board members is a expert in rare cardiovascular diseases and LMNA mutations, further supporting the medical relevance of our technology. We were also proud finalists in the Philips Innovation Award, one of the largest startup competitions for students and young adults in the Netherlands, and have received the TTT Medtech grant, which affirms the potential of our innovation.

Meer informatie over jouw initiatief / More info about your initiative

Vindi Biosystems is a TU Delft spin-off developing a photonic-based wearable medical device that continuously analyzes blood for 1 to 5 critical biomarkers. At the core of our technology is advanced photonic biosensing, which enables real-time, high-precision monitoring of physiological changes. By detecting early signs of disease or impending critical health events, before symptoms appear, our device helps reduce hospitalizations, readmissions, and length of hospital stays. Early detection also enables less invasive and more cost-effective disease management, improving patient outcomes while easing the burden on healthcare systems. Our mission is to move healthcare from reactive treatment to proactive prevention by setting a new standard in continuous, personalized monitoring.

Wat is er anders/nieuw aan jouw idee/oplossing t.o.v. bestaande oplossingen? / What is different/new about your idea/solution compared to existing solutions??

While continuous glucose monitors exist for diabetes management, there are currently no commercially available devices that offer continuous monitoring for a broader range of biomarkers relevant to other diseases. Traditional laminar flow tests are rarely prescribed to predict a critical health event, and most diagnostic tools are limited to detecting a single biomarker at a time. Our technology is designed to simultaneously monitor, starting at, five biomarkers in real time, making it uniquely suited to detect early warning signs of conditions such as heart failure, before they escalate into critical events. We believe it’s time to fundamentally rethink how we approach the care of chronic conditions.

Wat zijn jouw volgende stappen om het verder te ontwikkelen? / What are your next steps to develop the initiative?

Our current goal is to move from Technology Readiness Level TRL 3 to TRL 6, hence becoming more attractive to venture capital investors. To achieve this we are currently seeking funding to continue developing the technical capabilities of our wearable device. We are also expanding our advisory board to support this next phase. Specifically, we are looking for:

1. A regulatory expert to help navigate the medical device approval process.
2. An industry leader with experience in scaling healthcare technologies.
3. A practicing medical doctor who can provide clinical insight to ensure our solution aligns with real-world patient needs and workflows.

Wat heb je nodig om (nog meer) impact te maken met dit initiatief? / What do you need to make (more) impact with this initiative?

To maximize our impact, we need to raise awareness about the benefits of proactive healthcare, especially the importance of tracking biomarkers in asymptomatic individuals. Early detection can make the difference between manageable treatment and irreversible progression, both in terms of patient outcomes and healthcare costs.